Janssen’s Sirturo: TB Milestone Awaits After Advisory Committee Hurdle
This article was originally published in The Pink Sheet Daily
Executive Summary
Important safety questions remain for what could be the first new tuberculosis drug in 40 years, and there was a lack of efficacy in the key subgroup of black patients.